

Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg

Yi Gao, Ying Ma, Mei Li, Tong Cheng, Shao-Wei Li, Jun Zhang, Ning-Shao Xia

Yi Gao, Ying Ma, Tong Cheng, Shao-Wei Li, Jun Zhang, Ning-Shao Xia, The Key Laboratory Ministry of Education for Cell Biology and Tumor Cell Engineering, Xiamen University, Xiamen 361005, Fujian Province, China

Mei Li, Xiamen Overseas Chinese Introduction Garden, Xiamen 361002, Fujian Province, China

Supported by the grant from Natural Scientific Fundation of Fujian Province, No. C9910004 and Xiamen Kaili Biologic Product Limited Company

Correspondence to: Professor Ning-Shao Xia, The Key Laboratory Ministry of Education for Cell Biology and Tumor Cell Engineering, Xiamen University, Xiamen 361005, Fujian Province, China. nsxia@jingxian.xmu.edu.cn

Telephone: +86-592-2184110 **Fax:** +86-592-2184110

Received: 2002-12-07 **Accepted:** 2003-01-02

Abstract

AIM: To investigate the expression of recombinant HBsAg (rHBsAg) in transgenic cherry tomatillo in order to explore the feasibility of producing HBV oral vaccine with cherry tomatillo by animal immune tests.

METHODS: The recombinant plant expression vector containing HBsAg gene was constructed. Mediated with *Agrobacterium tumefaciens*, HBsAg gene was transferred into cotyledons of cherry tomatillo. Transformed cherry tomatillos were obtained through hygromycin delay-selection. Integrated DNA in transgenic cherry tomatillo was confirmed by hygromycin resistance selection, Gus detection, polymerase chain reaction (PCR) and dot blotting analysis. Antigenicity of rHBsAg was examined by ELISA and the immunogenicity of rHBsAg derived from transgenic cherry tomatillo tissues was confirmed by oral feed of transformed tissues to BALB/c mice primed with commercial HBV vaccines. Specific antibody titers in mice's serum were examined by ELISA every week.

RESULTS: By far, 10 positive lines of transgenic cherry tomatillos containing HBsAg gene were obtained. Among different organs of the same transgenic cherry tomatillo, level of rHBsAg expressed in leaves was the highest with the yield up to 300ng/g fresh weight. And the rHBsAg expression level in fruits was about 10 ng/g fresh weight. In animal immune tests, oral delivery with transgenic tissues to mice primed with commercial vaccine instead of naive mice resulted in significant immune response.

CONCLUSION: The result of this animal immune test indicated the rHBsAg derived from transgenic cherry tomatillo possessed normal immunogenicity. This work demonstrated the feasibility to generate oral immunogenic rHBsAg in transgenic cherry tomatillo, and would provide some experimental approach for the production of low-cost oral vaccines using transgenic cherry tomatillo in large scale.

Gao Y, Ma Y, Li M, Cheng T, Li SW, Zhang J, Xia NS. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. *World J Gastroenterol* 2003; 9(5): 996-1002 <http://www.wjgnet.com/1007-9327/9/996.htm>

INTRODUCTION

Hepatitis B virus infection is one of the most widespread viral infections of humans, especially in China. HBV DNA were found in most of newborns of HBsAg positive mothers^[1]. HBV vaccines have prevented numerous infections. However, administration of vaccine intramuscularly causes some pain, it is not accepted widely, especially in children. In recent years, a novel production system of vaccines- "edible vaccines" or "oral vaccines" is developed. Oral vaccines can serve multiple immunization priorities, including simplicity of use, increase in compliance (as a result of increased comfort of delivery), enhanced immune responses at mucosal sites, and stimulation of humoral immunity^[2-5].

The use of transgenic vegetables and fruits for the expression and delivery of recombinant protein antigens as edible vaccines has become an attractive topic for plant molecular biologists. Plants are potential source of antigen protein that is not dependent upon process technology to ensure protein folding and particle assembly. In addition, a plant-based antigen protein expression system makes possible the testing of an oral immunization strategy by simply feeding the plant tissues. So far, the production of oral vaccines in transgenic plant has focus on viral and bacterial subunit antigen, including *E.coli* heat-labile enterotoxin B subunit (LT-B)^[6-12], cholera toxin B subunit (CT-B)^[13,14], hepatitis B surface antigen (HBsAg)^[15-21], Norwalk virus capsid protein (NVCP)^[22,23], rabies virus glycoprotein^[24], etc. The results of oral immune tests in human bodies with transgenic potato and lettuce expressing rHBsAg have been reported, and the special antibody was detected in serum of the volunteers who were given edible tissues of transgenic plant^[25]. As we know, potato and lettuce could not be eaten in raw in certain population. But cooking process would destroy the target protein and affect its immunogenicity. So the plant acceptor should not only be easy to handle in genetic constructs, but also be able to be consumed in raw. In our study, we chose cherry tomatillo as the plant system for producing recombinant antigen.

Tomatillo, *Physalis ixocarpa* Brot. is grown in Mexico annually. It is a good source of vitamin C. The flesh of tomatillo is solid and seedy. And the pulp is glutinous, a little sweeter than tomato, and the flavor is somewhat similar to green apple. It is a key ingredient of many Mexican recipes, raw or cooked. Ripe fruits can be eaten raw, in sandwiches and salads. As an important commercial vegetable crop in the diets of Mexicans and Central Americans, tomatillo has been known by more and more researchers. The aim of this study that chose tomatillo as the plant acceptor was to investigate the feasibility of producing HBV oral vaccine with transgenic cherry tomatillo.

MATERIALS AND METHODS

Materials

Plant materials Cherry tomatillo (*Physalis ixocarpa* Brot.). The seeds were obtained from Xiamen ITG Seed IMP&EXP CO., LTD.

Bacterium and plasmids *Agrobacterium tumefaciens* strain EHA105, was kindly provided by Prof. Zhang Qi-fa, Huazhong Agricultural University. p1301HBs, recombinant mini Ti

commercially available enzyme immunoassay (EIA) diagnostic kit (Double Antigen sandwich-ELISA Kit, Beijing Wantai Biological Medicine Co.).

RESULTS

Transformation and regeneration of cherry tomatillo

The plasmid for expression of HBsAg in plants (p1301HBs, Figure 1) was introduced into *Agrobacterium tumefaciens* and used in transformation experiments. Hygromycin incorporated

into tissue culture media allowed for selection of transformed callus tissue from which shoots and thereafter mature cherry tomatillo plants were regenerated over a period of about 2-3 months. Ten independent hygromycin-resistant lines of transgenic plants were generated finally. Some lines grew poorly in tissue culture. Such effects could result from insertional mutagenesis. Four lines appearing similar in morphology to wild-type plants were transferred to a greenhouse for fruiting (Figure 2). And F1 progeny of one line was obtained.




Figure 2 Transgenic cherry tomatillo. A, Transgenic plant in tissue culture; B, Transgenic plant in greenhouse; C, Green transgenic fruits; D, Ripe transgenic fruits.




Figure 3 Analysis of Gus activity in transformed cherry tomatillo tissues. A, Leaf of transformed cherry tomatillo; B, Leaf of non-transformed cherry tomatillo; C, Fruit of transformed cherry tomatillo; D, Fruit of non-transformed cherry tomatillo.

Detection of expression activity of reporter gene (*Gus*)

The transformed plants, containing *Gus* gene as the report gene, were tested for the *Gus* activity (Figure 3). The results demonstrated that *Gus* gene was stably integrated into nuclear chromosomal DNA of tomatillo and different organs all presented a remarkably high *Gus* activity.

PCR screening for the presence of HBsAg gene

To verify that these plants contained the target gene, genomic DNA extracted from young leaves was subjected to PCR amplification and the PCR products were electrophoresed through agarose. Samples containing the target gene were identified by the presence of an amplified product of 480 bp, representing a fragment of the HBsAg-S coding sequence in p1301HBs. The results obtained demonstrated the presence of an amplified product of the expected size in all the hygromycin-resistant plants tested, which was absent in non-transformed plants (Figure 4 A).

Analysis of genomic DNA by dot blotting

To further confirm that HBsAg coding gene was stably integrated into nuclear chromosomal DNA of transgenic cherry tomatillo, genomic DNA was analyzed by dot blotting, which showed that all the transgenic samples had the same hybridization signals as the positive control (p1301HBs) (Figure 4 B).




Figure 4 Identification of HBsAg gene in transgenic cherry tomatillo by PCR (A) and dot blot (B). A1, DNA marker; A2, Positive Control; A3, Non-transformed plants; A4-9, Transformed plants. B1-6, Transformed plants; B7, Non-transformed plants; B8, Positive control.

Immunological detection and quantification of rHBsAg in transgenic tomatillo

Plants positive in PCR and dot blotting were further tested by ELISA to detect and quantitatively analyze the target protein. The rHBsAg levels in different organs from a representative one of several tactile lines are presented in Table 1. The results indicated that the expression levels of rHBsAg varied among different organs of the same plant. Apparently, the amount of rHBsAg produced in leaf was much higher than any of the other organs. rHBsAg protein levels in fruit and stem were in a similar range. However, rHBsAg/TSP (total soluble protein) value of fruit was somewhat higher than that of leaf. No

significant variation was observed among the rHBsAg/TSP values of the same kind of organs in different individuals reproduced from the same line, but striking difference in the absolute expression levels of rHBsAg was observed and the level of TSP in leaves of the plantlets in tissue culture was significantly lower than that in leaves of the plants in greenhouse. The difference might be due to growth condition of these plants.

The rHBsAg levels in leaves of tissue-cultured plantlets of four different lines were shown in Table 2. ELISA analysis demonstrated that rHBsAg was expressed in these different lines ranging from 21 to 90 nag/g fresh weight.

Table 1 Expression of HBsAg in different organs and different plants of same line

Plant No.	Organ	Total soluble protein (mg/g fresh weight)	Content of HBsAg (nag/g fresh weight)	HBsAg/TSP (1/1000 000)
1#	Leaf	31.6	300	9
	Stem	5.8	15	3
	Fruit	0.7	7	10
2#	Leaf	30.0	240	8
	Stem	5.0	9	2
	Fruit	0.6	6	10
3#	Leaf	27.3	210	8
	Stem	3.6	7	2
	Fruit	0.6	6	10
4#	Leaf	11.3	90	8
	Stem	2.6	5	2
CK	Leaf	28.4	-	-
	Stem	4.7	-	-
	Fruit	0.6	-	-

Note: 1#, 2#, 3#, 4# were different plants of same transgenic cherry tomatillo line; 1#, 2#, 3# were transferred to soil in the greenhouse; 4# was still in tissue culture; CK was a non-transformed plant growing in the greenhouse.

Table 2 Expressed target protein

Line No.	Total soluble protein (mg/g fresh weight)	Content of HBsAg (ng/g fresh weight)	HBsAg/TSP (1/1000 000)
1#	16.0	45	3
2#	15.5	24	2
3#	12.6	21	2
4#	13.1	90	7
CK	13.7	-	-

Note: 1#, 2#, 3# and 4# were four different lines of transgenic cherry tomatillo with normal phenotype, and these materials were all leaves of transgenic plants in the condition of tissue culture; CK was leaf of a non-transformed tomatillo in tissue culture.

Oral immunogenicity of rHBsAg derived from transgenic tomatillo in mice

The immunogenicity of plant-derived rHBsAg was tested by oral immunizing BALB/c mice with transgenic tissues from plant line with highest production of rHBsAg. Then vaccinated mice were bled weekly, and the sera were assessed for the presence of specific antibodies by ELISA.

Oral primary immunization

Oral immunization of two naive mice by feeding transgenic tissues did not evoke primary antibody within four weeks. Then mice in two groups were both injected with a subimmunogenic dose (0.5 μ g HBsAg) of commercial HBV vaccine via an

intramuscularly route as booster. However, none of the mice developed measurable specific serum antibodies in the following examination. There was no significant difference between serum antibody titers of the mice primed with transgenic tissues and those of the control mice in this experiment (Figure 5).




Figure 5 Serum antibody response elicited by oral prime with transgenic cherry tomatillo. A.B: Mice were fed non-transformed tissues until week 4, then boosted with a subimmunogenic dose of commercial vaccine; C.D: Mice were fed transformed tissues until week 4, then boosted parenterally with a subimmunogenic dose of commercial vaccine.

Oral booster immunization

After a single dose (2 μ g HBsAg) of commercial vaccine as priming, titers of serum antibody in mice rose sharply in response to antigen initially and then declined. Three mice primed were orally immunized with tissues of the transgenic tomatillo tissues as booster, and elicited an immediate high-level recall antibody response within the following 3-5 weeks. Antibody titers in serum were augmented significantly. In comparison, one negative control mouse fed with wild type tomatillo tissues did not show any booster response. Serum titers of antibody remained same (Figure 6).

We concluded that immune memory cells were established in mice following parenteral immunization of commercial vaccine and a recall response was elicited by oral delivery of HBsAg in transgenic tissues.

Our results showed that tomatillo-derived rHBsAg had same immunogenicity as commercial vaccine in stimulating production of HBsAg-specific antibodies in animal. The present experiment was limited by the total amount of plant tissues that mice ingested in 24 h and the amount of rHBsAg produced in the transgenic tissues. Absence of expected anti-HBsAg response in the oral priming study might be due to inadequate immunization schedule, such as low doses of antigen, or low sensitivity of the detection system and interference of plant material with development of an immune response. In contrast, active immune response to orally administered antigens in parenterally primed animals might be due to altered antigen processing in favoring of active antibody production rather than oral immunotolerance.

DISCUSSION

Oral vaccination using transgenic plants is a viable approach to the development of a novel HBV vaccine. Availability of the vaccine in an edible form as a fruit or vegetable would enhance vaccination coverage by providing an inexpensive, easy to deliver and relatively heat-stable package for distribution. Such a vaccine would have the potential to enable rates of vaccination to reach the targets required for global eradication.

In this study a new foreign breed of cherry tomatillo was used as the vector of producing transgenic plant vaccine. Through the research of transforming HBsAg gene into




Figure 6 Serum antibody response elicited by oral boost with transgenic cherry tomatillo. A: Mouse was primed parenterally with 2 μ g commercial rHBsAg, and when its serum antibody level descends to OD<1.0, mouse was fed with untransformed tissues; B.C.D: Mice were primed parenterally with 2 μ g yeast-derived rHBsAg, and when their serum antibody levels descend to OD<1.0, mice were fed with transformed tissues as boost.

tomatillo, a high efficient transformation system of tomatillo was produced, and the recombinant protein from transgenic plants possessed good immunogenicity. The work demonstrated the feasibility of expressing the oral immunogenic rHBsAg in transgenic tomatillo, and provided some theoretic and experimental directions for the production oral vaccines using transgenic tomatillo in large scale.

Transgenic plants expressing recombinant antigens have been developed successfully since it was first described by Mason *et al.* A corollary of this research is the goal of developing subunit vaccines that are produced in edible plant

products, such that the plant-derived vaccine can be ingested directly without prior purification or processing. It appears to be a very promising alternative to other methods for expressing recombinant protein. Nevertheless, a number of questions and challenges still remain to be solved. And its main disadvantage is low yields of antigen expressed. To our knowledge, in most cases at present expression levels of vaccine proteins in transgenic plants are lower than 0.1 %. We encountered the same problem in the study. Although plant-derived rHBsAg had good immunogenicity, the maximal level of rHBsAg in transgenic tomatillos was inadequate for use practically.

Bioencapsulation of the recombinant antigen within plant cells may protect it from degradation by gastrointestinal proteinases and allow important epitopes to be recognized. It may result in greater stability of the antigen in the stomach, effectively increasing the amount of antigen available for uptake in the gut. However, foreign antigens expressed in edible plant tissues for use as oral vaccines also will consist of impure mixtures with numerous other plant proteins. The stability of such a protein in the gut is unknown yet, but high protein levels and localization in the cell wall should ensure that at least some of the antigen will be delivered to the intestine. To address these possibilities, we need edible plant tissues that produce higher levels of rHBsAg, and thus our further studies will focus on increasing the accumulation of rHBsAg in transgenic tomatillos.

Over the past decade increasing endeavors have been directed towards how to augment expression levels of foreign genes in transgenic plants. Some modifications of expression vectors have been successfully assayed to have the function to lead to increased levels of expression of the recombinant genes, including the use of stronger promoters^[15], plant-optimized synthetic genes^[8], plant-derived leader sequences, signal peptides which can target the protein for retention in intercellular compartments^[7,10,27], the fruit-specific expressed promoter^[28,29], and the chloroplast expression system^[30] etc.

Although this study was not yet complete, we could demonstrate that plant-derived rHBsAg was active as an oral immunogen and cherry tomatillo might be a potential source of vaccines for direct application. Transgenic tomatillos could induce specific immune response depending on the route of administration and immune status of the animal. In our hands, oral immunization solely by feeding transgenic tissues was not effective. Activation of the immune system by a primary immunization via a parenteral route followed by booster via the oral route resulted in significant antibody responses. The results showed that the administration of edible vaccines in primed instead of naive subjects revealed a more sensitive test system and higher probability of success. The mechanisms underlying the increased responsiveness of parenterally primed animals to orally delivered antigens are not clear yet. Further research is required to optimize this approach and to identify the underlying mechanisms. Combinations of parenteral and oral delivery may eventually prove to be most efficient, and in this regard, the present study provides a platform for ongoing and future investigations.

In conclusion, more and more attentions have been paid to the study on oral vaccine using transgenic plants in the recent years, and many great achievements have been attained in this field. However, there is a long way to go before practical use of oral vaccine. Many problems still need to be solved, such as how to improve the accumulation of target protein in edible tissues of transgenic plant, how to enlarge the production scale of plant oral vaccine, how to properly determine the suitable delivery method and dosage of plant oral vaccine.

REFERENCES

- 1 **Wang SP**, Xu DZ, Yan YP, Shi MY, Li RL, Zhang JX, Bai GZ, Ma JX. Hepatitis B virus infection status in the PBMC of newborns of HBsAg positive mothers. *World J Gastroenterol* 2000; **6**(Suppl 3): 58
- 2 **Daniell H**, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccine in plants. *Trends Plant Sci* 2001; **6**: 219-226
- 3 **Walmsley AM**, Arntzen CJ. Plants for delivery of edible vaccines. *Curr Opin Biotechnol* 2000; **11**: 126-129
- 4 **Koprowski H**, Yusibov V. The green revolution: plants as heterologous expression vectors. *Vaccine* 2001; **19**: 2735-2741
- 5 **Liu DH**. Plant as a system for production of pharmaceutical proteins. *Shengwu Jishu Tongbao* 1999; **4**: 1-5
- 6 **Tacket CO**, Reid RH, Boedeker EC, Losonsky G, Nataro JP, Bhagat H, Edelman R. Enteral immunisation and challenge of volunteers given enterotoxigenic *E. coli* CFA/II encapsulated in biodegradable microspheres. *Vaccine* 1994; **12**: 1270-1274
- 7 **Haq TA**, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. *Science* 1995; **268**: 714-716
- 8 **Mason HS**, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against *Escherichia coli* heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. *Vaccine* 1998; **16**: 1336-1343
- 9 **Tacket CO**, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. *Nat Med* 1998; **4**: 607-609
- 10 **Lauterslager TG**, Florack DE, Wal TJ, Molthoff JW, Langeveld JP, Bosch D, Boersma WJ, Hilgers LA. Oral immunization of naive and primed animals with transgenic potato tubers expressing LT-B. *Vaccine* 2001; **19**: 2749-2755
- 11 **Streatfield SJ**, Jilka JM, Hood EE, Turner DD, Bailey MR, Mayor JM, Woodard SL, Beifuss KK, Horn ME, Delaney DE, Tizard IR, Howard JA. Plant-based vaccines: unique advantages. *Vaccine* 2001; **19**: 2742-2748
- 12 **Chikwamba R**, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K. A functional antigen in a practical crop: LT-B producing maize protects mice against *Escherichia coli* heat labile enterotoxin (LT) and cholera toxin (CT). *Transgenic Res* 2002; **11**: 479-493
- 13 **Arakawa T**, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. *Nat Biotechnol* 1998; **16**: 292-297
- 14 **Daniell H**, Lee SB, Panchal T, Wiebe PO. Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. *J Mol Biol* 2001; **311**: 1001-1009
- 15 **Mason HS**, Lam DMK, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. *Proc Natl Acad Sci USA* 1992; **89**: 11745-11749
- 16 **Richter LJ**, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. *Nat Biotechnol* 2000; **18**: 1167-1171
- 17 **Kong QX**, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with Hepatitis B surface antigen expressed in transgenic plants. *PNAS* 2001; **98**: 11539-11544
- 18 **Smith ML**, Mason HS, Shuler ML. Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. *Biotechnol Bioeng* 2002; **80**: 812-822
- 19 **Zhao CH**, Wang R, Zhao CS, Wang GL, Tian P. Expression of human hepatitis B virus surface antigen gene with and without preS in transgenic tomato. *Nongye Shengwu Jishu Xuebao* 2000; **8**: 85-88
- 20 **Chen HY**, Zhang J, Gao Y, Du HL, Ma Y, Zheng WZ, Xia NS. Transforming HBsAg into peanut and detection of its immunogenicity. *Shengwu Jishu Tongxun* 2002; **13**: 245-250
- 21 **Ma Y**, Lin SQ, Gao Y, Zhang J, Lu LX, Xia NS. Transformation of HBsAg (hepatitis B virus surface antigen) into tomato plants. *Fujian Nonglin Daxue Xuebao(Ziran Kexueban)* 2002; **31**: 223-227
- 22 **Mason HS**, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. *Proc Natl Acad Sci* 1996; **93**: 5335-5340

- 23 **Tacket CO**, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. *J Infect Dis* 2000; **182**: 302-305
- 24 **McGarvey PB**, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, Koprowski H, Michaels FH. Expression of the rabies virus glycoprotein in transgenic tomatoes. *Biotechnology* 1995; **13**: 1484-1487
- 25 **Kapusta J**, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. A plant-derived edible vaccine against hepatitis B virus. *FASEB J* 1999; **13**: 1796-1799
- 26 **Wang GL**, Fang HJ. Principle and technology of plant genetic engineering, 1st ed, Beijing: *Science Press* 1998
- 27 **Tackaberry ES**, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. *Vaccine* 1999; **17**: 3020-3029
- 28 **Clendennen SK**, López-Gómez R, Gómez-Lim M, May GD, Arntzen CJ. The abundant 31-kilodalton banana pulp protein is homologous to class-III acidic chitinases. *Phytochemistry* 1998; **47**: 613-619
- 29 **Sandhu JS**, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE. Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. *Transgenic Res* 2000; **9**: 127-135
- 30 **Cosa BD**, Moar W, Lee SB, Miller M, Daniell H. Over-expression of the Bt Cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. *Nat Biotechnol* 2001; **19**: 71-74

Edited by Ren SY